Physician profile
William Daniel Doty
NPI 1558361063
$2,071.12
in general payments reported to CMS, 2019-2025
22 companies · $391 in 2025
The $391 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118 · 2020: $88.12 · 2021: $301 · 2022: $483 · 2023: $328 · 2024: $362 · 2025: $391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,081.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,081.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $333.34 | 2021-2025 | Verquvo |
| Amgen INC. | $295.81 | 2021-2024 | Repatha |
| Novartis Pharmaceuticals Corporation | $284.06 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $229.96 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $154.68 | 2019-2022 | |
| Kestra Medical Technology Services, INC. | $127.39 | 2025 | Assure Wcd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.00 | 2019 | |
| Pfizer INC. | $86.36 | 2020-2024 | |
| Boston Scientific Corporation | $71.14 | 2023-2025 | Watchman Access System, Watchman |
| Actelion Pharmaceuticals US, INC. | $58.15 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $55.47 | 2020-2023 | Camzyos |
| Lexicon Pharmaceuticals, INC. | $43.84 | 2023-2024 | Inpefa |
| Esperion Therapeutics, INC. | $37.41 | 2023-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $33.15 | 2023-2025 | |
| Philips North America LLC | $31.74 | 2024 | (Ck7) Extended Holter |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $31.14 | 2025 | Arexvy, Shingrix |
| Kiniksa Pharmaceuticals International, Plc | $22.01 | 2024 | Arcalyst |
| Agepha Pharma Fz LLC | $20.64 | 2025 | Lodoco |
| Irhythm Technologies, INC. | $17.44 | 2023 | Zio Xt Patch |
| Abb Con-Cise Optical Group LLC | $17.17 | 2025 | Spectacle Lenses |
| Inspire Medical Systems, INC. | $15.72 | 2025 | Inspire |
| Kowa Pharmaceuticals America, INC. | $14.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Doty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.